Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

Abstract Background A nadir Prostate-Specific Antigen (nPSA) of 0.06 ng/mL has been shown to be a strong independent predictor of biochemical recurrence-free survival (bRFS) in patients with intermediate or high-risk (HR) prostate cancer treated with definitive external beam radiation therapy (RT) a...

Full description

Bibliographic Details
Main Authors: Zeina Ayoub, Jamal Khader, Muhammad Bulbul, Raja B. Khauli, Therese Y. Andraos, Ali Shamseddine, Deborah Mukherji, Fady B. Geara
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Urology
Subjects:
Prostate cancer
Nadir PSA
Androgen deprivation therapy
Online Access:https://doi.org/10.1186/s12894-022-01145-x

Internet

https://doi.org/10.1186/s12894-022-01145-x

Similar Items